title: The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome.
abstract: BACKGROUND
  The aim of this study was to establish the outcome of renal transplantation in patients given pretransplant erythropoietin (EPO) treatment targeted at reaching a normal hemoglobin concentration (Hb), compared to those given EPO-treatment aimed at maintaining subnormal Hb.
  
  
  METHODS
  A total of 416 patients from Scandinavian countries and with renal anaemia were enrolled to examine the effects of increasing Hb from a subnormal level (90-120 g/liter) to a normal level (135-160 g/liter) by EPO treatment. Half of the patients were randomized to have their Hb increased, with the other half randomized to maintain a subnormal Hb. Thirty-two patients from the normal Hb group and 24 patients from the subnormal group received a renal graft during the study period. The outcomes of these transplantations were examined prospectively for 6 months.
  
  
  RESULTS
  Preoperative Hb levels were 143+/-17 and 121+/-14 g/liter in the two groups, respectively (P<0.0001). The Hb remained higher in the normal Hb group during the first 2 weeks after transplantation. The percentage of patients requiring postoperative blood transfusions in the normal Hb group was 16%, compared with 50% in the subnormal group (P<0.01). No statistically significant difference in the proportion of functioning grafts or in the serum creatinine levels could be detected. No correlation between EPO treatment and creatinine levels after transplantation was found. The frequency of adverse events was similar in the two groups.
  
  
  CONCLUSIONS
  EPO treatment aimed at reaching a normal Hb in renal transplant recipients reduces the postoperative requirement for blood transfusions and has no deleterious effects on kidney graft function.
authors.affiliation: Department of Medical Sciences, University Hospital, Uppsala, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Linde
authors.forename: H
authors.initials: H
authors.lastname: Ekberg
authors.forename: T
authors.initials: T
authors.lastname: Forslund
authors.forename: H
authors.initials: H
authors.lastname: Furuland
authors.forename: H
authors.initials: H
authors.lastname: Holdaas
authors.forename: G
authors.initials: G
authors.lastname: Nyberg
authors.forename: G
authors.initials: G
authors.lastname: Tydén
authors.forename: J
authors.initials: J
authors.lastname: Wahlberg
authors.forename: B G
authors.initials: BG
authors.lastname: Danielson
mesh_terms: D000328:Adult; D000368:Aged; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin